Biofrontera acquires full US rights to Ameluz and RhodoLED from former parent
PositiveFinancial Markets

Biofrontera has successfully acquired full rights to its products Ameluz and RhodoLED in the US from its former parent company. This move is significant as it allows Biofrontera to have complete control over its product distribution and marketing strategies in a key market, potentially leading to increased sales and brand recognition. The acquisition reflects Biofrontera's commitment to expanding its presence in the dermatology sector and enhancing patient access to its innovative treatments.
— Curated by the World Pulse Now AI Editorial System